Other Corporate Information-arkiv - Page 3 of 16

Isofol includes first patient in a clinical phase Ib/II study of arfolitixorin

GOTHENBURG, Sweden, April 28, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the first patient has been […]

GOTHENBURG, Sweden, April 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s Japanese development and

GOTHENBURG, Sweden, March 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has established

GOTHENBURG, Sweden, March 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the regulatory authority in

GOTHENBURG, Sweden, March 17, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has expanded

GOTHENBURG, Sweden, March 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company’s CEO will present

GOTHENBURG, Sweden, March 5, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces that the company will participate in

GOTHENBURG, Sweden, February 3, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roger Tell has been

GOTHENBURG, Sweden, January 27, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that an abstract of the

GOTHENBURG, Sweden, December 18, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), today announces that its partner Solasia Pharma